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Abstract 
Background 
Aortic valve pre-dilation with Balloon Aortic Valvuloplasty (BAV) is recommended 
prior to Transcatheter Aortic Valve Implantation (TAVI), despite limited data around the 
requirement of this pre-procedural step and the potential risks of embolisation. This study 
aimed to investigate the trends in practice and associations of BAV on short-term outcomes 
in the UK TAVI registry. 
Methods and Results 
 Eleven clinical endpoints were investigated including 30-day mortality, myocardial 
infarction, aortic regurgitation, valve dysfunction and composite early safety. All endpoints 
were defined as per the VARC-2 definitions. Odd ratios of each endpoint were estimated 
using logistic regression, with data analysed in balloon-expandable and self-expandable valve 
subgroups. Propensity scores were calculated using patient demographics and procedural 
variables, which were included in the models of each endpoint to adjust for measured 
confounding. 
Between 2007 and 2014, 5887 patients met the study inclusion criteria, 1421 (24.1%) 
of whom had no BAV before TAVI valve deployment. We observed heterogeneity in the use 
of BAV nationally, both temporally and by centre experience; rates of BAV in pre-TAVI 
work-up varied between 30% and 97% across TAVI centres. All endpoints were similar 
between treatment groups in SAPIEN valve patients. After correction for multiple testing, 
none of the endpoints in CoreValve patients were significantly different between patients 
with or without pre-dilation.  
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Conclusions 
Performing TAVI without pre-dilation was not associated with adverse short-term 
outcomes post procedure, especially when using a balloon-expandable prosthesis. 
Randomised trials including different valve types are required to provide conclusive evidence 
regarding the utility of pre-dilation before TAVI. 
Keywords  
Transcatheter aortic valve implantation - balloon-expandable - self-expandable – balloon 
valvuloplasty – aortic stenosis 
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Introduction 
Transcatheter aortic valve implantation (TAVI) is an effective treatment option for 
multi-morbid patients with severe symptomatic aortic stenosis (AS) who are either not 
suitable for conventional surgical aortic valve replacement or who are deemed high-risk 
surgical candidates 1–4. 
During the TAVI procedure, recommendations have included the use of balloon aortic 
valvuloplasty (BAV) to pre-dilate the aortic valve before the deployment of the transcatheter 
valve. Such pre-dilation is intended to aid delivery of the prosthesis across the valve, enhance 
prosthesis expansion in the aortic annulus, provide information about the aortic annulus size 
and potentially improve hemodynamic performance during the TAVI procedure 5. 
Additionally, BAV during TAVI can be used to evaluate possible coronary occlusion in 
patients with low coronary height. However, BAV is associated with complications, 
including stroke, conduction disturbances and severe aortic regurgitation 6,7. Thus, it is 
possible that the routine use of BAV in TAVI procedures actually increases procedural risk. 
Whilst it is routine for many TAVI centres to pre-dilate using BAV, recent preliminary 
studies have indicated that TAVI without pre-dilation is feasible in both Edwards SAPIEN 
and Medtronic CoreValve prostheses 8–14. However, much of the previously published data in 
this area is derived from small single-centre studies and subject to sampling bias, with little 
data on utility of BAV and its associated clinical outcomes following TAVI in large multi-
centre TAVI registries.  
Therefore, this analysis was undertaken in the UK TAVI registry to investigate 
patterns of BAV use across the UK and its association with short-term clinical outcomes 
following TAVI. 
5 
 
Methods 
UK TAVI Registry 
The UK TAVI registry uses a Web-based interface provided by the National Institute 
of Cardiovascular Outcomes Research to collect data prospectively on every TAVI procedure 
conducted in the UK 15. There are currently thirty-four centres running active TAVI 
programs, with data collection being mandatory 15. The dataset comprises ninety-five 
variables, detailing patient demographics, risk factors for intervention, procedural details and 
adverse outcomes up to the time of hospital discharge. Patient life status is provided by 
record linkage with the Office for National Statistics for English and Welsh patients. 
Mortality information for Northern Irish patients and the majority of Scottish patients was 
unavailable and consequently these patients were removed from the analysis. 
This study analysed data from January 2007 to December 2014. The Edwards 
SAPIEN (Edwards Lifesciences Inc., Irvine, CA, USA) and the Medtronic CoreValve 
(Medtronic, Minneapolis, MN, USA) prostheses were available to all centres throughout the 
study period.  
Study Design 
Endpoints in this study were 30-day mortality and the following events occurring up 
to hospital discharge: myocardial infarction (MI), stroke, paravalvular leak (PVL) / moderate-
severe aortic regurgitation (AR), coronary artery obstruction (CAO), valve dysfunction 
requiring repeat procedure, permanent pacemaker implantation (PPM) requirement, device 
migration, kidney injury, major vascular complications (MVC) and composite early safety. 
All endpoints were defined as given in the VARC-2 definitions 16.  
This analysis defined BAV procedures based on when any such procedure was 
completed relative to the time of TAVI. Specifically, we distinguished the following timings: 
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(1) BAVs completed prior to the date of TAVI (Prior-TAVI BAV), (2) BAVs completed as 
part of the TAVI procedure but before valve deployment (During-TAVI BAV) and (3) no 
BAV prior or during the TAVI procedure (Direct TAVI). Since the aim of this study was to 
investigate the effect of pre-dilation on TAVI outcomes, the main analysis excluded any 
patient who had a BAV prior to the date of TAVI; hence, the main analysis compared 
endpoints across patients with a During-TAVI BAV (but none prior) and Direct TAVI, with 
the latter group taken as the reference. All patients with missing treatment group identifiers 
were excluded.  
Additionally, to investigate if the timing of the BAV relative to the TAVI procedure 
was associated with outcomes, we conducted a sensitivity analysis that did not exclude those 
patients who had a BAV prior to the date of TAVI. Hence, the sensitivity analysis compared 
outcomes across all four possible treatment groups: (i) Prior-TAVI BAV and During-TAVI 
BAV; (ii) Prior-TAVI BAV & No During-TAVI BAV; (iii) No Prior-TAVI BAV & During-
TAVI BAV; and (iv) No Prior-TAVI BAV & No During-TAVI BAV (Direct TAVI). Here, 
groups (iii) and (iv) comprised exactly those patients as in the main analysis. 
Since the effects of BAV on outcomes after TAVI were potentially dependent on the 
expansion method of the valve type (balloon-expandable or self-expandable), all analyses 
were completed in device specific subgroups (SAPIEN vs CoreValve). Patients were 
excluded only from the valve-subgroup analyses if they were not treated with a SAPIEN or 
CoreValve prosthesis or if the valve type was unknown. 
Statistical Analysis 
Continuous data were presented as means and standard deviations with group 
comparisons done with analysis of variance. Categorical data were presented as counts and 
percentages with group comparisons done using the chi-squared test.  
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Every variable with missing data was imputed using multiple imputation 17. Ten 
imputed datasets were generated using multiple imputation by chained equations. The 
imputation model for each variable included the majority of other variables in the UK TAVI 
registry. Additionally, to avoid underestimation of covariate-outcome associations, all 
endpoints were used in the imputation models for missing covariates 18. After such 
imputation, the imputed outcome values were returned to the original values (i.e. missing), 
following the so-called multiple imputation, then deletion approach 19. All patients with 
missing life-status were excluded from the analysis; patients with other endpoints missing 
were only excluded from the analysis of that particular endpoint. Analyses were undertaken 
in each dataset separately, before pooling results according to Rubin’s rules 17.  
To investigate clinical outcomes across treatment groups, propensity scores (PS) for 
being in each treatment group were calculated for all patients to control for potential 
confounders and baseline differences 20,21. A logistic regression model calculated each 
patient’s PS, given the baseline covariates, which included every variable listed in Table 1 
(except the LES and STS score), in addition to a TAVI centre experience indicator and year 
of procedure. For the sensitivity analysis, a multinomial logistic regression model was used to 
calculate each patient’s PS for each treatment group, which included exactly the same 
covariates as for the main analysis. Odds ratios (ORs) for each endpoint across BAV 
treatment groups were estimated using a logistic regression model that was fitted to each 
outcome with the treatment group indicator and the PS as covariates. A Bonferroni correction 
was applied to account for multiple testing.  
Patient characteristics that resulted in a higher probability to perform pre-dilation 
were identified by deriving a logistic regression model with During-TAVI BAV (no prior 
BAV) as the dependent variable. Predictors associated with the use of pre-dilation were 
investigated by backwards selection using Akaike information criterion (AIC) in each 
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imputed dataset, resulting in ten (potentially different) sets of selected predictors. Predictors 
that were selected in more than 50% of the ten imputed datasets were identified as 
independent predictors of During-TAVI BAV, following the so-called “majority method” of 
selecting variables in multiple imputed data 22. Given the selected predictors, a logistic 
regression model was fitted in each of the ten imputed datasets with estimated coefficients 
and standard errors then pooled according to Rubin’s rules 17. 
R version 3.3.1 23 was used for all statistical analyses. Graphical plots where made 
using the ggplot2 package 24 and the mice package was used for the multiple imputation 25.  
Results 
From January 2007 to December 2014, 7431 patients underwent a TAVI procedure in 
the UK. The flow of patients through the steps of exclusion criteria is illustrated in Figure 1. 
Specifically, the analysis set for the main analysis comprised of 5887 patients; 1421 patients 
(24.1%) had no BAV (Direct TAVI) and 4466 patients (75.9%) had a During-TAVI BAV. 
Together, 3201 patients had a SAPIEN valve, 2467 patients had a CoreValve and the 
remaining 219 patients were treated with another or unknown valve type. For the sensitivity 
analysis, which did not exclude prior-to-TAVI BAV patients, the analysis set included 
exactly those patients in the main analysis in addition to 507 patients who had a Prior & 
During-TAVI BAV and 197 patients who had a Prior-TAVI BAV but no During-TAVI BAV.  
Summary statistics of baseline characteristics for the main analysis are given in Table 
1. The During-TAVI BAV group had significantly higher mean age and higher proportions of 
patients with extracardiac arteriopathy, calcification of ascending aorta, NYHA class III or 
IV, and one or more disease coronary vessels, but significantly smaller proportions of 
patients with previous cardiac surgery and pulmonary hypertension. Patients in the During-
TAVI BAV group had a significantly smaller mean aortic valve area and significantly larger 
aortic peak gradient than in the Direct TAVI group (p<0.01), although the proportion of 
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patients with impaired Left Ventricular function at the time of the TAVI procedure was 
similar (p=0.47). The Logistic EuroSCORE (LES) and STS score models were calculated in 
each multiply imputed dataset using the variables and coefficients previously published 26,27. 
Hence, the ranges of the mean and standard deviations across each imputed dataset are given; 
predicted risk as estimated by both models was significantly different across treatment groups 
(Table 1).  
Trends in BAV Practice 
Between 2007 and 2014 there was a decreasing trend in the proportion of patients 
undergoing pre-dilation in the whole cohort (p<0.001) and by access route (p=0.001) (Figure 
2). A similar pattern of longitudinal behaviour was observed over SAPIEN and CoreValve 
patients. Additionally, there was heterogeneity in practice amongst centres, with During-
TAVI BAV group rates varying from 30% to 97% (Figure 3). Interestingly, there was a 
visual trend of decreased use of BAV for successive increases in centre experience, with the 
exception of the two very highest volume groups (251-300 and 300+), which represented just 
seven centres (Figure 4). Specifically, when a centre had undertaken between 1 and 50 
previous TAVI procedures, rates of During-TAVI BAV were 89%, but this had decreased to 
50% when centres had undertaken between 201 and 250 previous TAVIs. 
TAVI Outcomes by BAV Treatment Group 
Table 2 gives the PS adjusted odds ratios for each outcome in the whole cohort for 
the main analysis. Before adjusting for multiple testing, patients with a During-TAVI BAV 
had increased odds of having a permanent pacemaker (OR of 1.30). However, this was not 
significant after correcting for multiplicity (Table 2). There were no other significant 
differences in other endpoints between the two treatment groups. Similar findings were 
obtained in the sensitivity analysis of the four-treatment groups (Table 3). 
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When studying patients treated with the balloon-expandable SAPIEN valve, there 
were no significant differences in any of the endpoints between During-TAVI BAV and 
Direct TAVI treatment groups (Table 4). For the self-expanding CoreValve prosthesis, 
before multiplicity correction the During-TAVI BAV group had significantly lower odds of 
valve dysfunction (OR of 0.58) over those undergoing Direct TAVI. However, this finding 
was not significant after multiplicity correction (Table 4). Other endpoints were not 
significantly different across treatment groups in the CoreValve subgroup. Similar findings 
for the SAPIEN and CoreValve subgroups were observed in the sensitivity analysis of the 
four-treatment-group analysis (Table 5 and Table 6). 
Predictors of During-TAVI BAV 
 Variables that were independently associated with the use of pre-dilation are given in 
Figure 5. Odds of undergoing During-TAVI BAV were significantly lower with increasing 
year of procedure and with increasing number of TAVI procedures for a given centre, which 
supports the trend analysis after multivariable adjustment. Additionally, female patients with 
larger aortic valve area, previous cardiac surgery, pulmonary hypertension and non-elective 
procedures were significantly less likely to undergo a During-TAVI BAV. Conversely, 
calcification of ascending aorta, NYHA class III or IV and transfemoral access were 
associated with significantly increased odds of During-TAVI BAV.  
Discussion 
This analysis of 5887 UK TAVI procedures has shown heterogeneity in the use of 
BAV nationally. Importantly, outcomes were not significantly different between patients who 
had a Direct TAVI and those who only had a BAV as part of the TAVI procedure. Notably, 
there were no significant differences in all outcomes across any of the treatment groups in 
SAPIEN valve patients. Similarly, after correction for multiple testing, there were no 
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significant differences between those with and without BAV in patients treated with a 
CoreValve prosthesis. These findings support those from a recent meta-analysis, which 
showed similar outcomes after TAVI both with and without pre-dilation 13. 
Although using BAV pre-TAVI may help to prepare the calcified aortic valve, 
standalone BAV procedures are associated with several complications 6,28; hence, removing 
the pre-dilation step may simplify the TAVI procedure. This study highlighted that the 
proportion of TAVI patients in the UK having a BAV in pre-TAVI work-up is decreasing 
through time. Despite pre-dilation before TAVI valve deployment being the most common 
procedure throughout the majority of UK TAVI centres, several centres conducted relatively 
high proportions of Direct TAVI procedures. The reasons behind these changes in procedure 
are unclear from the current work, but certainly translate the progress along the learning 
curve that leads to more confidence with direct implantation.  
BAV Outcomes in SAPIEN Valve patients 
An important finding of the current study was that there were no significant 
differences over any of the clinical outcomes between treatment groups in the SAPIEN valve 
patients. These results are consistent with previous studies 8,9,12,14,29. A study that compared 
50 transapical access patients with BAV to 50 transapical access patients without BAV, 
found no significant differences in any of the endpoints defined in the VARC-2 definitions 8; 
this finding was later supported with studies on transfemoral access SAPIEN-TAVI patients 
9. In contrast, previous work has suggested that SAPIEN-TAVI without BAV is associated 
with higher volume of cerebral ischemic lesions 30. In the current study, differences between 
stroke outcomes over the two treatment groups were not significant. Once published, findings 
from a planned multicentre two-armed observational trial (EASE-IT) comparing SAPIEN 
TAVI patients with or without pre-dilation, will provide further insights 31. The present study 
suggests that SAPIEN TAVI procedures can feasibly be conducted without routine BAV, 
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without increased risk in adverse outcomes. However, a degree of selection on a patient level 
is advocated, likely based on the extent of calcification and movement of leaflets, but also 
based on if a patient has impaired LV function where one might want to minimise pacing 
time during TAVI. 
BAV Outcomes in CoreValve patients 
After correction for multiple testing, there were no significant differences with and 
without pre-dilation in CoreValve patients. When testing many endpoints, one would expect 
to find positive results by chance simply due to the way hypothesis testing is conducted 32. 
Nonetheless, the feasibility of conducting TAVI without BAV in CoreValve patients was first 
proposed in a pilot study of 60 patients 11. Subsequent studies have shown that clinical 
outcomes are similar between BAV treatment groups in CoreValve patients 10,33,34. 
Theoretically, conducting TAVI without BAV in self-expanding valves could potentially lead 
to worse outcomes. For example, without BAV, self-expanding valves may not achieve as 
good expansion and may therefore fail to reach optimal deployment dimensions, particularly 
in heavily calcified aortic annuli. While the current study highlights the potential to remove 
the pre-dilation step in CoreValve TAVI procedures with regard to clinical outcomes, further 
work in this subgroup of patients will be required. For example, it is possible that patients 
undergoing CoreValve TAVI without prior BAV will require post-dilatation more frequently 
to correct for stent under expansion and/or paravalvular leakage. The majority of patients in 
the current study did not have data on post-dilation requirement and so this endpoint could 
not be analysed. 
Timing of BAV Relative to TAVI 
We hypothesised a priori that the timing and indication for performing BAV could be 
related to the impact on subsequent clinical outcomes. Consequently, the sensitivity analysis 
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included those patients who had a BAV as a bridge to TAVI (i.e. a BAV completed prior to 
the date of the TAVI procedure), who represent a specific complex group of patients. All 
outcomes were similar between those who had a BAV prior to the date of TAVI (with or 
without subsequent BAV during TAVI) and those undergoing Direct TAVI. However, 
although we were able to distinguish the patients who had a BAV as a bridge to TAVI, the 
UK registry does not capture the reasons a BAV was conducted. Hence, this study could not 
investigate the full impact of BAVs conducted prior-to-TAVI. Prior-to-TAVI dilation is often 
conducted when a patient has presented with severe AS or when there are questions regarding 
the clinical benefit of a TAVI procedure. Therefore, one could argue that TAVI might not be 
feasible in such cases, without the period of convalescence after the preparatory BAV. 
Further work in such patients is recommended, as there is a paucity of data for this specific 
cohort of patients. 
Limitations 
One limitation of the current work is that outcomes associated with the decision to use 
BAV were studied in this retrospective study. Such a design may introduce significant 
selection biases since the UK TAVI registry does not capture the reasons why or how each 
BAV was conducted. As such, any reported relationships cannot be interpreted as causal and 
they may relate to unmeasured confounders or selection bias. The inclusion of most patient 
demographic, procedural information and TAVI centre experience in the PS models should 
mitigate the effects of this as much as possible. Likewise, patients who undergo a BAV are 
generally more severe cases with complex anatomy and would hence be expected to have 
poorer outcomes over those who do not undergo BAV, the use of PS in the correct work aims 
to correct for such confounding by indication. Finally, the absence of information regarding 
hemodynamic performance, valve failure rates and echocardiographic outcomes means that 
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such outcomes were unable to be analysed. Similarly, we were unable to investigate technical 
difficulties, which have previously been indicated in Direct TAVI patients 14. 
Conclusion 
This large-scale study highlights that a no-BAV (Direct TAVI) approach has similar 
clinical outcomes to the current practice of using BAV to pre-dilate the diseased valve, 
especially when using a balloon-expandable prosthesis. Although this analysis provides 
evidence that omitting the BAV step is feasible, this warrants prospective randomised studies 
to define further the utility of BAV.  
Acknowledgements 
We would like to acknowledge the National Institute for Cardiovascular Outcomes Research 
(NICOR) for provided the UK TAVI registry extract for this study.  
Funding 
This research was funded by the Medical Research Council, through the Health e-Research 
Centre, University of Manchester [MR/K006665/1] and the North Staffordshire Heart 
Committee.  
Conflict of Interest Disclosures 
None. 
 
15 
 
References 
1.  Leon M, Smith C, Mack M, Miller DC, Moses JW, Svensson LG, Tuzcu EM, Webb 
JG, Fontana GP, Makkar RR, Brown DL, Block PC, Guyton RA, Pichard AD, Bavaria 
J, Herrmann HC, Douglas PS, Petersen J, Akin JJ, Anderson WN, Wang D, Pocock S. 
Transcatheter aortic-valve implantation for aortic stenosis in patients who cannot 
undergo surgery. N Engl J Med. 2010;363:1597–1607. 
2.  Ludman PF, Moat N, de Belder MA, Blackman DJ, Duncan A, Banya W, MacCarthy 
PA, Cunningham D, Wendler O, Marlee D, Hildick-Smith D, Young CP, Kovac J, 
Uren NG, Spyt T, Trivedi U, Howell J, Gray H. Transcatheter Aortic Valve 
Implantation in the UK: Temporal Trends, Predictors of Outcome and 6 Year Follow 
Up: A Report from the UK TAVI Registry 2007 to 2012. Circulation. 2015;131:1181–
1190. 
3.  Moat NE, Ludman P, de Belder MA, Bridgewater B, Cunningham AD, Young CP, 
Thomas M, Kovac J, Spyt T, MacCarthy PA, Wendler O, Hildick-Smith D, Davies 
SW, Trivedi U, Blackman DJ, Levy RD, Brecker SJD, Baumbach A, Daniel T, Gray 
H, Mullen MJ. Long-Term Outcomes After Transcatheter Aortic Valve Implantation in 
High-Risk Patients With Severe Aortic Stenosis. J Am Coll Cardiol. 2011;58:2130–
2138. 
4.  Smith C, Leon M, Mack M, Miller DC, Moses JW, Svensson LG, Tuzcu EM, Webb 
JG, Fontana GP, Makkar RR, Williams M, Dewey TM, Kapadia S, Babaliaros V, 
Thourani VH, Corso P, Pichard AD, Bavaria J, Herrmann HC, Akin JJ, Anderson WN, 
Wang D, Pocock S. Transcatheter versus surgical aortic-valve replacement in high-risk 
patients. N Engl J Med. 2011;364:2187–2198. 
16 
 
5.  Vahanian A, Himbert D. Transcatheter Aortic Valve Implantation. JACC Cardiovasc 
Interv. 2011;4:758–759. 
6.  Ben-Dor I, Pichard AD, Satler LF, Goldstein SA, Syed AI, Gaglia MA, Weissman G, 
Maluenda G, Gonzalez MA, Wakabayashi K, Collins SD, Torguson R, Okubagzi P, 
Xue Z, Kent KM, Lindsay J, Waksman R. Complications and Outcome of Balloon 
Aortic Valvuloplasty in High-Risk or Inoperable Patients. JACC Cardiovasc Interv. 
2010;3:1150–1156. 
7.  Sack S, Kahlert P, Khandanpour S, Naber C, Philipp S, Möhlenkamp S, Sievers B, 
Kälsch H, Erbel R. Revival of an old method with new techniques: balloon aortic 
valvuloplasty of the calcified aortic stenosis in the elderly. Clin Res Cardiol. 
2008;97:288–297. 
8.  Conradi L, Seiffert M, Schirmer J, Koschyk D, Blankenberg S, Reichenspurner H, 
Diemert P, Treede H. Transapical transcatheter aortic valve implantation without prior 
balloon aortic valvuloplasty: feasible and safe. Eur J Cardio-Thoracic Surg. 
2014;46:61–66. 
9.  Conradi L, Schaefer A, Seiffert M, Schirmer J, Schaefer U, Schön G, Blankenberg S, 
Reichenspurner H, Treede H, Diemert P. Transfemoral TAVI without pre-dilatation 
using balloon-expandable devices: a case-matched analysis. Clin Res Cardiol. 
2015;104:735–742. 
10.  Fiorina C, Maffeo D, Curello S, Lipartiti F, Chizzola G, D’Aloia A, Adamo M, 
Mastropierro R, Gavazzi E, Ciccarese C, Chiari E, Ettori F. Direct transcatheter aortic 
valve implantation with self-expandable bioprosthesis: Feasibility and safety. 
Cardiovasc Revascularization Med. 2014;15:200–203. 
17 
 
11.  Grube E, Naber C, Abizaid A, Sousa E, Mendiz O, Lemos P, Kalil Filho R, Mangione 
J, Buellesfeld L. Feasibility of Transcatheter Aortic Valve Implantation Without 
Balloon Pre-Dilation. JACC Cardiovasc Interv. 2011;4:751–757. 
12.  Kempfert J, Meyer A, Kim W-K, van Linden A, Arsalan M, Blumenstein J, Mollmann 
H, Walther T. First experience without pre-ballooning in transapical aortic valve 
implantation: a propensity score-matched analysis. Eur J Cardio-Thoracic Surg. 
2015;47:31–38. 
13.  Bagur R, Kwok CS, Nombela‐-Franco L, Ludman PF, de Belder MA, Sponga S, 
Gunning M, Nolan J, Diamantouros P, Teefy PJ, Kiaii B, Chu MWA, Mamas MA. 
Transcatheter Aortic Valve Implantation With or Without Preimplantation Balloon 
Aortic Valvuloplasty: A Systematic Review and Meta Analysis. J Am Heart Assoc. 
2016;5:e003191. 
14.  Bernardi FLM, Ribeiro HB, Carvalho LA, Sarmento-Leite R, Mangione JA, Lemos 
PA, Abizaid A, Grube E, Rodés-Cabau J, de Brito FS. Direct Transcatheter Heart 
Valve Implantation Versus Implantation With Balloon Predilatation. Circ Cardiovasc 
Interv. 2016;9:e003605. 
15.  Ludman PF. The UK transcatheter aortic valve implantation registry; one of the suite 
of registries hosted by the National Institute for Cardiovascular Outcomes Research 
(NICOR). Heart. 2012;98:1787–1789. 
16.  Kappetein AP, Head SJ, Genereux P, Piazza N, van Mieghem NM, Blackstone EH, 
Brott TG, Cohen DJ, Cutlip DE, van Es G-A, Hahn RT, Kirtane AJ, Krucoff MW, 
Kodali S, Mack MJ, Mehran R, Rodes-Cabau J, Vranckx P, Webb JG, Windecker S, 
Serruys PW, Leon MB. Updated standardized endpoint definitions for transcatheter 
18 
 
aortic valve implantation: the Valve Academic Research Consortium-2 consensus 
document. Eur Heart J. 2012;33:2403–2418. 
17.  Rubin DB. Multiple Imputation for Nonresponse in Surveys. John Wiley & Sons; 
1987.  
18.  Sterne JAC, White IR, Carlin JB, Spratt M, Royston P, Kenward MG, Wood AM, 
Carpenter JR. Multiple imputation for missing data in epidemiological and clinical 
research: potential and pitfalls. BMJ. 2009;338:b2393–b2393. 
19.  von Hippel PT. Regression with Missing YS: An Improved Strategy For Analyzing 
Multiply Imputed Data. Sociol Methodol. 2007;37:83–117. 
20.  Rosenbaum PR, Rubin DB. The Central Role of the Propensity Score in Observational 
Studies for Causal Effects. Biometrika. 1983;70:41–55.  
21.  Rosenbaum PR, Rubin DB. Reducing Bias in Observational Studies Using 
Subclassification on the Propensity Score. J Am Stat Assoc. 1984;79:516–524.  
22.  Vergouwe Y, Royston P, Moons KGM, Altman DG. Development and validation of a 
prediction model with missing predictor data: a practical approach. J Clin Epidemiol. 
2010;63:205–214. 
23.  R Core Team R. R: A Language and Environment for Statistical Computing [Internet]. 
R Found. Stat. Comput. 2016;Available from: http://www.r-project.org/ 
24.  Wickham H. ggplot2: elegant graphics for data analysis. Springer New York; 2009. 
25.  Buuren S Van, Groothuis-Oudshoorn K. mice: Multivariate Imputation by Chained 
Equations in R. J Stat Softw. 2011;45:1–67. 
19 
 
26.  Roques F. The logistic EuroSCORE. Eur Heart J. 2003;24:882. 
27.  O’Brien SM, Shahian DM, Filardo G, Ferraris VA, Haan CK, Rich JB, Normand S-
LT, DeLong ER, Shewan CM, Dokholyan RS, Peterson ED, Edwards FH, Anderson 
RP. The Society of Thoracic Surgeons 2008 Cardiac Surgery Risk Models: Part 2—
Isolated Valve Surgery. Ann Thorac Surg. 2009;88:S23–S42. 
28.  Tissot C-M, Attias D, Himbert D, Ducrocq G, Iung B, Dilly M-P, Juliard J-M, Lepage 
L, Détaint D, Messika-Zeitoun D, Nataf P, Vahanian A. Reappraisal of percutaneous 
aortic balloon valvuloplasty as a preliminary treatment strategy in the transcatheter 
aortic valve implantation era. EuroIntervention. 2011;7:49–56. 
29.  Möllmann H, Kim W-K, Kempfert J, Blumenstein J, Liebetrau C, Nef H, Van Linden 
A, Walther T, Hamm C. Transfemoral Aortic Valve Implantation of Edwards SAPIEN 
XT Without Predilatation Is Feasible. Clin Cardiol. 2014;37:667–671. 
30.  Bijuklic K, Haselbach T, Witt J, Krause K, Hansen L, Gehrckens R, Rieß F-C, Schofer 
J. Increased Risk of Cerebral Embolization After Implantation of a Balloon-
Expandable Aortic Valve Without Prior Balloon Valvuloplasty. JACC Cardiovasc 
Interv. 2015;8:1608–1613. 
31.  Bramlage P, Strauch J, Schröfel H. Balloon expandable transcatheter aortic valve 
implantation with or without pre-dilation of the aortic valve – rationale and design of a 
multicenter registry (EASE-IT). BMC Cardiovasc Disord. 2014;14:160-165. 
32.  Sedgwick P. Pitfalls of statistical hypothesis testing: multiple testing. BMJ. 
2014;349:g5310–g5310. 
33.  Giustino G, Montorfano M, Latib A, Panoulas VF, Chieffo A, Spatuzza P, Ferre GF, 
20 
 
Agricola E, Spagnolo P, Covello RD, Alfieri O, Colombo A. TCT-743 To Predilate or 
To Not Predilate In Transcatheter Aortic Valve Implantation? Single-Center 
Experience With Self-Expandable CoreValve Revalving System. J Am Coll Cardiol. 
2014;64:B217–B218. 
34.  Mendiz OA, Fraguas H, Lev GA, Valdivieso LR, Favaloro RR. Transcatheter aortic 
valve implantation without balloon predilation: A single-center pilot experience. 
Catheter Cardiovasc Interv. 2013;82:292–297. 
21 
 
Figure Legends 
Figure 1: Flowchart illustrating the exclusion criteria applied to the UK TAVI registry.  
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Figure 2: The longitudinal changes in the proportion of TAVI patients having During-TAVI 
BAV (no BAV prior to TAVI) and Direct TAVI in the whole cohort and by access route.  
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Figure 3: The proportion of patients having During-TAVI BAV (no BAV prior to TAVI) and 
Direct TAVI over the 32 centres running active TAVI programs in the England and Wales by 
2014. The centres on the x-axis have been sorted based on the total number of TAVI 
procedures each has conducted. 
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Figure 4: The proportion of patients in each treatment group by centre experience. The x-
axis shows the number of TAVI procedures conducted within a centre prior to each patient 
within that centre. 
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Figure 5: Odds ratios of variables that were identified as independent predictors of a patient 
being in the During-TAVI BAV group. 
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Tables 
Table 1. Baseline characteristics across the treatment groups in the main analysis that 
excluded BAVs conducted prior-to-TAVI.  
Variable Whole 
Cohort 
(n=5887) 
During-
TAVI BAV 
(n=4466) 
Direct TAVI 
(n=1421) 
p-value Missing 
(%) 
Age, mean (SD) 81.3 (7.5) 81.5 (7.2) 80.5 (8.2) <0.001 0 (0.00) 
Female, n (%) 2755 (46.8) 2125 (47.6) 630 (44.3) 0.03 21 (0.36) 
Diabetic, n (%) 1351 (22.9) 1019 (22.8) 332 (23.4) 0.70 6 (0.10) 
Smoker, n (%) 3051 (51.8) 2351 (52.6) 700 (49.3) 0.10 201 (3.4) 
Creatinine, mean 
(SD) 
113.7 (64.9) 112.8 (64.0) 116.3 (67.5) 0.08 44 (0.75) 
Renal Failure *, n 
(%) 
351 (6.0) 250 (5.6) 101 (7.1) 0.05 72 (1.2) 
Previous MI, n (%) 1246 (21.2) 936 (21.0) 310 (21.8) 0.50 6 (0.10) 
Pulmonary Disease, 
n (%) 
1648 (28.0) 1262 (28.3) 386 (27.2) 0.38 51 (0.9) 
Neurological 
Disease, n (%) 
1011 (17.2) 790 (17.7) 221 (15.6) 0.07 6 (0.10) 
Extracardiac 
Arteriopathy, n (%)  
1390 (23.6) 1085 (24.3) 305 (21.5) 0.02 51 (0.87) 
Calcification of 
Ascending Aorta, % 
1106 (18.8) 923 (20.7) 183 (12.9) <0.001 44 (0.75) 
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(n) 
Atrial Fibrillation, n 
(%) 
1434 (24.4) 1071 (24.0) 363 (25.5) 0.28 68 (1.2) 
Previous Cardiac 
Surgery, n (%) 
1884 (32.0) 1299 (29.1) 585 (41.2) <0.001 6 (0.10) 
Previous PCI, n (%) 1141 (19.4) 877 (19.6) 264 (18.6) 0.40 6 (0.10) 
Height, mean (SD) 1.65 (0.10) 1.64 (0.10) 1.65 (0.10) 0.01 110 (1.9) 
Weight, mean (SD) 74.1 (16.4) 73.9 (16.4) 74.8 (16.4) 0.06 87 (1.5) 
CCS Class 4, n (%) 70 (1.2) 53 (1.2) 17 (1.2) 0.99 10 (0.17) 
NYHA ≥ III, n (%) 4708 (80.0) 3642 (81.5) 1066 (75.0) <0.001 15 (0.25) 
Pulmonary 
Hypertension, n (%) 
677 (11.5) 499 (11.2) 178 (12.5) 0.001 1652 
(28.1) 
Aortic Valve Area, 
mean (SD) 
0.68 (0.22) 0.66 (0.20) 0.74 (0.28) <0.001 325 (5.5) 
Aortic Valve Peak 
Gradient, mean 
(SD) 
75.6 (25.9) 78.4 (25.4) 66.3 (25.5) <0.001 222 (3.8) 
LVEF < 50%, n (%) 2160 (36.7) 1628 (36.5) 532 (37.4) 0.47 28 (0.48) 
One or more 
diseased vessels, n 
(%) 
2507 (42.6) 1952 (43.7) 555 (39.1) 0.001 71 (1.2) 
Left Main Stem 
Disease, n (%) 
271 (4.6) 215 (4.8) 56 (3.9) 0.22 102 (1.7) 
Non-elective 702 (11.9) 478 (10.7) 224 (15.8) <0.001 2 (0.03) 
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Procedure, n (%) 
LES, mean (SD) † 21.4 – 21.5 
(13.7-13.9) 
21.4-21.5 ± 
13.4-13.5 
22.8-23.2 ± 
14.8-15.1 
<0.001 NA 
STS Score, mean 
(SD) † 
4.9-5.0 (4.0-
4.1) 
5.0-5.0 ± 3.7-
3.8 
5.1-5.2 ± 4.6-
4.7 
0.01 NA 
Access Site     5 (0.08) 
      Transfemoral, n 
(%) 
4385 (74.5) 3326 (74.5) 1059 (74.5) 0.92  
     Transapical, n 
(%) 
952 (16.2) 709 (15.9) 243 (17.1) 0.28  
     Subclavian, n 
(%) 
223 (3.8) 194 (4.3) 29 (2.0) <0.001  
     Other, n (%) 322 (5.5) 235 (5.3) 87 (6.1) 0.23  
* Defined as creatinine >200µmol/l or dialysis for renal failure. † The Logistic EuroSCORE and STS models 
were calculated using the imputed data and so ranges are given for these variables for the summary measures 
across the ten multiply imputed datasets; variables that were included in either model but were not recorded in 
the UK TAVI registry were assumed risk factor absent. LES: Logistic EuroSCORE, LVEF: Left Ventricular 
Ejection Fraction, MI: Myocardial Infarction, NYHA: New York Heart Association, PCI: Percutaneous 
coronary intervention, STS: Society of Thoracic Surgeons Score for Prediction of Mortality 
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Table 2. Crude event rates and PS regression adjusted odds ratios (OR) for each of the 
considered outcomes in the whole cohort for the main analysis that excluded BAVs 
conducted prior-to-TAVI. 
Outcome During-TAVI 
BAV (n=4466) 
Direct 
TAVI 
(n=1421) 
PS adjusted 
OR (95% CI) 
without 
Bonferroni 
correction 
PS adjusted 
OR (95% CI) 
with 
Bonferroni 
correction 
30-day mortality 239/4466 
(5.4%) 
63/1421 
(4.4%) 
1.04 (0.76, 
1.42) 
1.04 (0.63, 
1.72) 
MI 36/4442 
(0.81%) 
8/1411 
(0.57%) 
1.03 (0.45, 
2.35) 
1.03 (0.27, 
3.93) 
Stroke  132/4445 
(3.0%) 
35/1409 
(2.5%) 
0.91 (0.60, 
1.37) 
0.91 (0.47, 
1.77) 
Moderate/ Severe 
AR/PVL 
432/4043 
(10.7%) 
79/1314 
(6.0%) 
1.30 (0.99, 
1.69) 
1.30 (0.84, 
2.00) 
CAO 35/4441 
(0.79%) 
12/1410 
(0.85%) 
0.80 (0.39, 
1.65) 
0.80 (0.25, 
2.59) 
Valve Dysfunction  136/4426 
(3.1%) 
40/1407 
(2.8%) 
0.78 (0.53, 
1.15) 
0.78 (0.41, 
1.47) 
Pacemaker 
implantation  
520/4439 
(11.7%) 
130/1405 
(9.3%) 
1.30 (1.04, 
1.62) 
1.30 (0.91, 
1.86) 
Device Migration 72/4437 (1.6%) 24/1402 
(1.7%) 
1.21 (0.72, 
2.03) 
1.21 (0.52, 
2.80) 
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Haemofiltration/ 
Dialysis 
178/4426 
(4.0%) 
70/1405 
(5.0%) 
0.89 (0.65, 
1.22) 
0.89 (0.53, 
1.48) 
MVC  177/4431 
(4.0%) 
56/1407 
(4.0%) 
0.84 (0.60, 
1.18) 
0.84 (0.49, 
1.45) 
Early Safety 1114/4386 
(25.4%) 
276/1391 
(19.8%) 
0.98 (0.83, 
1.15) 
0.98 (0.75, 
1.27) 
AR: Aortic Regurgitation, CAO: Coronary Artery Obstruction, CI: Confidence Interval, MI: Myocardial 
Infarction, MVC: Major Vascular Complication, PVL: paravalvular leakage.
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Table 3. PS adjusted odds ratios (after Bonferroni correction) for each of the considered 
outcomes in the whole cohort for the sensitivity analysis. Note that the Direct-TAVI group 
was taken as the reference. 
Outcome OR (95% CI) Prior 
& During TAVI 
BAV (n=507) 
OR (95% CI) Prior & 
Not During TAVI 
BAV (n=197) 
OR (95% CI) Not 
Prior & During TAVI 
BAV (n=4466) 
30-day mortality 1.69 (0.79, 3.59) 1.01 (0.29, 3.49) 1.01 (0.59, 1.75) 
MI 1.13 (0.12, 10.32) NA 0.96 (0.22, 4.15) 
Stroke  0.79 (0.24, 2.60) 0.57 (0.07, 4.80) 0.88 (0.42, 1.82) 
Moderate/ 
Severe AR/PVL 
1.60 (0.83, 3.07) 0.93 (0.30, 2.89) 1.28 (0.80, 2.06) 
CAO 0.23 (0.01, 8.94) 0.61 (0.02, 23.89) 0.81 (0.22, 2.94) 
Valve 
Dysfunction  
0.58 (0.19, 1.80) 0.54 (0.06, 4.54) 0.68 (0.34, 1.38) 
Pacemaker 
implantation  
0.97 (0.50, 1.87) 0.99 (0.39, 2.50) 1.28 (0.86, 1.89) 
Device 
Migration 
1.54 (0.38, 6.23) 1.10 (0.13, 9.74) 1.16 (0.46, 2.91) 
Dialysis 1.02 (0.41, 2.53) 0.98 (0.30, 3.23) 0.91 (0.52, 1.58) 
MVC  0.66 (0.23, 1.90) 0.82 (0.19, 3.47) 0.83 (0.46, 1.50) 
Early Safety 0.97 (0.62, 1.52) 0.87 (0.43, 1.74) 0.94 (0.71, 1.26) 
CI: Confidence Interval, MI: Myocardial Infarction, AR: Aortic Regurgitation, PVL: paravalvular leakage, 
CAO: Coronary Artery Obstruction, MVC: Major Vascular Complication 
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Table 4. Crude event rates and PS regression adjusted odds ratios (OR) for each of the considered outcomes by valve type for the main analysis 
that excluded BAVs conducted prior-to-TAVI. 
 SAPIEN Valve patients (n=3201) CoreValve patients (n=2467) 
Outcome During-
TAVI 
BAV 
(n=2336) 
Direct 
TAVI 
(n=865) 
PS adjusted 
OR (95% CI) 
without 
Bonferroni 
correction 
PS adjusted 
OR (95% CI) 
with 
Bonferroni 
correction 
During-
TAVI 
BAV 
(n=1978) 
Direct 
TAVI 
(n=489) 
PS adjusted 
OR (95% CI) 
without 
Bonferroni 
correction 
PS adjusted 
OR (95% CI) 
with 
Bonferroni 
correction 
30-day mortality 137/2336 
(5.9%) 
40/865 
(4.6%) 
1.13 (0.76, 
1.68) 
1.13 (0.59, 
2.15) 
98/1978 
(5.0%) 
22/489 
(4.5%) 
0.80 (0.46, 
1.38) 
0.80 (0.33, 
1.93) 
MI 17/2322 
(0.73%) 
6/862 
(0.70%) 
0.73 (0.27, 
2.02) 
0.73 (0.14, 
3.79) 
17/1968 
(0.86%) 
1/482 
(0.21%) 
2.17 (0.26, 
18.3) 
2.17 (0.07, 
68.61) 
Stroke  55/2325 
(2.4%) 
23/860 
(2.7%) 
0.63 (0.37, 
1.08) 
0.63 (0.26, 
1.51) 
72/1969 
(3.7%) 
12/482 
(2.5%) 
0.97 (0.48, 
1.95) 
0.97 (0.31, 
3.01) 
Moderate/ 121/2072 32/800 1.11 (0.72, 1.11 (0.55, 306/1830 46/453 1.15 (0.79, 1.15 (0.63, 
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Severe AR/PVL  (5.8%) (4.0%) 1.71) 2.23) (16.7%) (10.2%) 1.68) 2.12) 
CAO 19/2320 
(0.82%) 
7/860 
(0.81%) 
0.84 (0.32, 
2.19) 
0.84 (0.18, 
3.97) 
14/1970 
(0.71%) 
5/484 
(1.0%) 
0.41 (0.13, 
1.35) 
0.41 (0.06, 
2.81) 
Valve 
Dysfunction  
50/2315 
(2.2%) 
14/858 
(1.6%) 
1.12 (0.58, 
2.16) 
1.12 (0.39, 
3.25) 
83/1964 
(4.2%) 
25/483 
(5.2%) 
0.58 (0.34, 
0.99) 
0.58 (0.24, 
1.40) 
PPM  127/2324 
(5.5%) 
45/858 
(5.2%) 
1.18 (0.80, 
1.76) 
1.18 (0.63, 
2.24) 
363/1967 
(18.5%) 
67/480 
(14.0%) 
1.26 (0.91, 
1.74) 
1.26 (0.74, 
2.13) 
Device 
Migration 
29/2325 
(1.2%) 
4/858 
(0.47%) 
2.65 (0.86, 
8.14) 
2.65 (0.43, 
16.32) 
40/1964 
(2.0%) 
18/481 
(3.7%) 
0.91 (0.45, 
1.83) 
0.91 (0.29, 
2.83) 
Haemofiltration/ 
Dialysis 
116/2311 
(5.0%) 
44/859 
(5.1%) 
0.95 (0.64, 
1.42) 
0.95 (0.50, 
1.82) 
62/1966 
(3.2%) 
23/480 
(4.8%) 
0.91 (0.50, 
1.65) 
0.91 (0.35, 
2.39) 
MVC  97/2316 
(4.2%) 
31/857 
(3.6%) 
0.98 (0.62, 
1.54) 
0.98 (0.47, 
2.04) 
77/1966 
(3.9%) 
21/483 
(4.3%) 
0.79 (0.44, 
1.40) 
0.79 (0.31, 
2.01) 
Early Safety 573/2282 
(25.1%) 
154/852 
(18.1%) 
1.07 (0.86, 
1.34) 
1.07 (0.75, 
1.53) 
521/1957 
(26.6%) 
111/473 
(23.5%) 
0.85 (0.65, 
1.12) 
0.85 (0.54, 
1.32) 
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AR: Aortic Regurgitation, CAO: Coronary Artery Obstruction, CI: Confidence Interval, MI: Myocardial Infarction, MVC: Major Vascular Complication, PPM: Pacemaker 
implantation, PVL: paravalvular leakage 
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Table 5. PS adjusted odds ratios (after Bonferroni correction) for each of the considered 
outcomes in the SAPIEN subgroup for the sensitivity analysis. Note that the Direct-TAVI 
group was taken as the reference. 
Outcome  OR (95% CI) Prior 
& During TAVI 
BAV 
OR (95% CI) Prior 
& no During TAVI 
BAV 
OR (95% CI) no 
Prior & During 
TAVI BAV 
30-day mortality 1.71 (0.65, 4.44) 1.10 (0.27, 4.53) 1.08 (0.54, 2.17) 
MI 0.84 (0.06, 11.85) NA 0.70 (0.11, 4.23) 
Stroke  0.84 (0.20, 3.50) 0.51 (0.04, 6.99) 0.61 (0.23, 1.58) 
Moderate/ Severe 
AR/PVL 
1.36 (0.47, 3.92) 1.15 (0.25, 5.32) 1.13 (0.53, 2.41) 
CAO NA 0.82 (0.02, 36.94) 0.83 (0.15, 4.59) 
Valve Dysfunction  0.95 (0.16, 5.73) 0.47 (0.01, 18.03) 0.99 (0.31, 3.12) 
Pacemaker 
implantation  
0.91 (0.28, 2.95) 1.43 (0.39, 5.20) 1.13 (0.57, 2.25) 
Device Migration 5.91 (0.53, 65.82) NA 2.79 (0.38, 20.74) 
Haemofiltration/ 
Dialysis 
1.03 (0.34, 3.12) 1.23 (0.34, 4.50) 1.01 (0.50, 2.03) 
MVC  0.49 (0.11, 2.29) 0.74 (0.11, 5.02) 0.94 (0.42, 2.09) 
Early Safety 1.01 (0.56, 1.83) 1.03 (0.45, 2.39) 1.03 (0.70, 1.52) 
CI: Confidence Interval, MI: Myocardial Infarction, AR: Aortic Regurgitation, PVL: paravalvular leakage, 
CAO: Coronary Artery Obstruction, MVC: Major Vascular Complication 
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Table 6. PS adjusted odds ratios (after Bonferroni correction) for each of the considered 
outcomes in the CoreValve subgroup for the sensitivity analysis. Note that the Direct-TAVI 
group was taken as the reference. 
Outcome OR (95% CI) Prior 
& During TAVI 
BAV 
OR (95% CI) Prior 
& no During TAVI 
BAV 
OR (95% CI) no 
Prior & During 
TAVI BAV 
30-day mortality 1.71 (0.46, 6.42) 0.84 (0.06, 12.13) 0.86 (0.33, 2.26) 
MI NA NA 2.91 (0.06, 137.8) 
Stroke  0.48 (0.05, 5.09) NA 0.96 (0.28, 3.30) 
Moderate/ Severe 
AR/PVL 
1.90 (0.77, 4.65) 0.68 (0.12, 4.00) 1.13 (0.58, 2.17) 
CAO 0.40 (0.01, 22.63) NA 0.46 (0.06, 3.78) 
Valve Dysfunction  0.60 (0.14, 2.62) 0.64 (0.04, 9.23) 0.55 (0.21, 1.44) 
Pacemaker 
implantation  
1.14 (0.45, 2.86) 0.80 (0.18, 3.63) 1.26 (0.71, 2.23) 
Device Migration 1.21 (0.15, 10.03) 1.34 (0.12, 15.03) 0.89 (0.26, 3.06) 
Haemofiltration/ 
Dialysis 
0.84 (0.13, 5.51) 0.37 (0.01, 14.33) 0.88 (0.31, 2.53) 
MVC  0.75 (0.14, 4.00) 1.43 (0.15, 13.91) 0.74 (0.27, 2.07) 
Early Safety 0.98 (0.47, 2.05) 0.69 (0.18, 2.61) 0.82 (0.51, 1.34) 
CI: Confidence Interval, MI: Myocardial Infarction, AR: Aortic Regurgitation, PVL: paravalvular leakage, 
CAO: Coronary Artery Obstruction, MVC: Major Vascular Complication 
 
